medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Number 1

<< Back Next >>

Rev Invest Clin 2005; 57 (1)

Sentinel lymph node biopsy in colorectal cancer: A pilot study

Medina-Franco H, Takahashi T, González-Ruiz GF, De-Anda J, Velazco L

Language: English
References: 28
Page: 49-54
PDF size: 70.25 Kb.


ABSTRACT

Background. Although sentinel lymph node biopsy technique is the gold standard in the management of malignant melanoma and is gradually replacing conventional axillary dissection in breast cancer, its use in colorectal cancer is still controversial. The objective of this study is to demonstrate the feasibility and safety of sentinel node biopsy in the management of colorectal carcinoma. Methods. Consecutive patients with colorectal carcinoma without preoperative evidence of nodal or distant metastatic disease were included. Intraoperative subserosal injection of 1mL of isosulfan blue (Lymphazurin ®) was performed around the tumor in cases of colon cancer and ex-vivo infiltration was used for rectal cancer after resection was completed. Blue stained nodes were dissected and submitted for routine pathology exam. If nodes were deemed negative for neoplasm, immunohistochemistry for cytokeratin was performed. The specimen and non-stained nodes were resected and processed in the usual fashion. Sensitivity and negative predictive value were calculated and adverse effects to the blue dye were registered. Results. Ten patients were included with at least one sentinel lymph node identified in each. Mean number of sentinel and non-sentinel lymph nodes were 2.5 and 15.6 per patient, respectively. The sensitivity and negative predictive value of the sentinel node after immunohistochemistry were both 100%. There were no adverse effects caused by the dye. Conclusions. Sentinel lymph node biopsy technique in colorectal cancer is feasible, has a high diagnostic accuracy and is harmless.


REFERENCES

  1. Fielding LP, Phillips RK, Fry JS, Hittinger R. Prediction of outcome after curative resection for large bowel cancer. Lancet 1986; 2: 904-7.

  2. Cohen AM, Tremiterra S, Candela F, Thaler HT, Sigurdson ER. Prognosis of node-positive colorectal cancer. Cancer 1991; 67: 1859-61.

  3. Malassagne B, Valleur P, Serra J, et al. Relationship of apycal node involvement to survival in resected colon carcinoma. Dis Colon Rectum 1993; 36: 645-53.

  4. Hayashi N, Ito I, Yanagisawa A, Kato Y, Nakamori S, Imaoka S, Watanabe H, Ogawa N, Nakamura Y. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995; 345: 1257-9.

  5. Liefers GJ, Cleton-Jansen AM, Van de Velde CJ, Hermans J, Van Krieken JH, Cornelisse CJ, Tollenaar RA. Micrometastasses and survival in stage II colorectal cancer. N Engl J Med 1998; 339:223-8.

  6. Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review. J Surg Oncol 1998; 67: 194-202.

  7. Krag ND. Minimal access surgery for staging regional lymph nodes: the sentinel node concept. Curr Prob Surg 1998; 35: 953-1017.

  8. Shida H, Ban K, Matsumoto M, et al. Prognostic significance of location of lymph node metastases in colorectal cancer. Dis Colon Rectum 1992; 35: 1046-50.

  9. Tang R, Wang JY, Chen JS, et al. Survival impact of lymph node metastasis in TNM stage III carcinoma of the colon and rectum. J Am Coll Surg 1995; 180: 705-12.

  10. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224: 255-66.

  11. Greco M, Agresti R, Raselli R, Giovanazzi R, Veronesi U. Axillary dissection can be avoided in selected breast cancer patients: analysis of 401 cases. Anticancer Res 1996; 16: 3913-17.

  12. Pezin ME, Nicholls RJ. Survival after high or low ligation of the inferior mesenteric artery during curative surgery for rectal cancer. Ann Surg 1984; 200: 729-33.

  13. Surtees P, Ritchie JK, Phillips RK. High versus low ligation of the inferior mesenteric artery in rectal cancer. Br J Surg 1990; 77: 618-21.

  14. Cady B. Lymph node metastases. Indicators, but not governors of survival. Arch Surg 1984; 119: 1067-72.

  15. NIH Consensus Conference. Adjuvant therapy for patient with colon and rectal cancer. JAMA 1990; 264: 1444-50.

  16. Wong JA, Steinman S, Calderia C, Bowies J, Namiki T. Ex vivo sentinel node mapping in carcinoma of the colon and rectum. Ann Surg 2001; 233: 515-21.

  17. Turner RR, Ollila DW, Stern S, Giuliano AE. Optimal histopathologic examination of the sentinel node for breast cancer staging. Am J Surg Pathol 1999; 23: 263-7.

  18. Koren R, Siegal A, Klein B, Halpern M, Kyzer S, Veltman V, Gal R. Lymph node-reveling solution: simple new method for detecting minute lymph nodes in colon carcinoma. Dis Colon Rectum 1997; 40: 407-10.

  19. Wood TF, Nora DT, Morton DL, Turner RR, Rangel D, Hutchinson W, Bilchik AJ. One hundred consecutive cases of sentinel lymph node mapping in early colorectal carcinoma: detection of missed micrometastasis. J Gastrointest Surg 2002; 6: 322-30.

  20. Merrie AEH, Van Rij AM, Phillips LV, Rossaak JI, Yun K, McCall JL. Diagnostic use of the sentinel node in colon cancer. Dis Colon Rectum 2001; 44: 410-7.

  21. Trocha SD, Nora DT, Saha SS, Morton DL, Wiese D, Bilchik AJ. Combination probe and dye-directed lymphatic mapping detects micrometastases in early colorectal cancer. J Gastrointest Surg 2003; 7: 340-6.

  22. Mori M, Mimori K, Ueo H, Tsuji K, Shiraishi T, Barnard GF, Sugimachi K, Akiyoshi T. Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas. J Clin Oncol 1998; 16: 128-32.

  23. Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg 2000; 232: 58-65.

  24. Ellis LM. A perspective on sentinel lymph node biopsy in colorectal cancer: The race between surgical technology and molecular oncology. Ann Surg Oncol 2000; 7: 475-6.

  25. Cutait R, lves VA, Lopes LC, Cutait DE, Borges JL, Singer J, Da Silva JH, Goffi FS. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum 1991; 34: 917-20.

  26. Jeffers MD, O’Dowd GM, Mulcahy H, Stagg M, O’Donoghue DP, Toner M. The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma. J Pathol 1994; 172: 183-7.

  27. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J, Rockette H. Comparative efficacy of adjuvant chemotherapy in patients with Duke’s B versus Duke’s C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349-55.

  28. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluoruracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17: 1356-63.




2020     |     www.medigraphic.com